Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'

被引：2
作者：
Bose, Prithviraj [1 ]
Chen, Lisa S. [2 ]
Gandhi, Varsha [1 ,2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 07期
关键词：
TYROSINE KINASE; THERAPY;
D O I：
10.1080/10428194.2019.1571207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1603 / 1605
页数：3
相关论文
共 15 条
  • [1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [2] Akhtar OS, 2019, LEUKEMIA LYMPHOMA, P1
  • [3] [Anonymous], BLOOD
  • [4] Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
    Barr, Paul M.
    Brown, Jennifer R.
    Hillmen, Peter
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Reddy, Nishitha M.
    Coutre, Steven
    Mulligan, Stephen P.
    Jaeger, Ulrich
    Furman, Richard R.
    Cymbalista, Florence
    Montillo, Marco
    Dearden, Claire
    Robak, Tadeusz
    Moreno, Carol
    Pagel, John M.
    Burger, Jan A.
    Suzuki, Samuel
    Sukbuntherng, Juthamas
    Cole, George
    James, Danelle F.
    Byrd, John C.
    [J]. BLOOD, 2017, 129 (19) : 2612 - 2615
  • [5] Bose Prithviraj, 2017, F1000Res, V6, P1924, DOI 10.12688/f1000research.11618.1
  • [6] Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
    Bose, Prithviraj
    Gandhi, Varsha V.
    Keating, Michael J.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (11) : 1381 - 1392
  • [7] Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
    Cervantes-Gomez, F.
    Patel, V. Kumar
    Bose, P.
    Keating, M. J.
    Gandhi, V.
    [J]. LEUKEMIA, 2016, 30 (08) : 1803 - 1804
  • [8] A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
    Chen, Lisa S.
    Bose, Prithviraj
    Cruz, Nichole D.
    Jiang, Yongying
    Wu, Qi
    Thompson, Philip A.
    Feng, Shuju
    Kroll, Michael H.
    Qiao, Wei
    Huang, Xuelin
    Jain, Nitin
    Wierda, William G.
    Keating, Michael J.
    Gandhi, Varsha
    [J]. BLOOD, 2018, 132 (21) : 2249 - 2259
  • [9] Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)
    Iskierka-Jazdzewska, Elzbieta
    Hus, Marek
    Giannopoulos, Krzysztof
    Madro, Elzbieta
    Holojda, Jadwiga
    Piotrowska, Magdalena
    Zaucha, Jan M.
    Piszczek, Weronika
    Szeremet, Agnieszka
    Wojciechowska, Malgorzata
    Steckiewicz, Pawel
    Knopinska-Posluszny, Wanda
    Osowiecki, Marek
    Drozd-Sokolowska, Joanna
    Kumiega, Beata
    Kyrcz-Krzemien, Slawomira
    Halka, Janusz
    Dudzinski, Marek
    Wieszczy, Paulina
    Robak, Tadeusz
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2485 - 2488
  • [10] Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
    Jain, Preetesh
    Thompson, Philip A.
    Keating, Michael
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    Kantarjian, Hagop
    Burger, Jan A.
    O'Brien, Susan
    Wierda, William G.
    [J]. CANCER, 2017, 123 (12) : 2268 - 2273
12